Lupin: Focus on inhalation and bio-similars to aid margins in medium term Trading Calls - Equity F&O May 14, 2021Recommendations In the medium term, the focus is likely to be on the inhalation and biosimilar categories for Lupin, with scale-up in both US and European markets Anubhav Sahu